Dexcom CGM is suitable for anyone with type 1, type 2 or gestational diabetes over the age of 2 years.* Whether treated with insulin injections or insulin pump therapy, they can benefit from real-time continuous glucose monitoring (rt-CGM).
Dexcom CGM can empower patients
Despite their best intentions and efforts, many patients with diabetes struggle to maintain optimal
glycaemic control.
A more complete picture of their diabetes and deeper insights for enhanced diabetes management
Accuracy that allows your patients to manage their glucose levels with confidence, leading to better outcomes
A convenient, patient-friendly experience that encourages more use for the best possible outcomes
Why Choose Dexcom G7 for your patients? Powerfully Simple Glucose Monitoring
Adults 65+ report high usability
with a set up time of
12.6 minutes1
Customised alerts to suit people living with
diabetes’ lifestyle and needs with the new
Delayed 1st High Alert
Silence All
Easy to insert: Simple, painless, one-push
applicator with all-in-one sensor2
The group of Certified Diabetes Care and
Education Specialists (CDCES) from our study
could set up Dexcom G7 in 7 minutes. G7 has
half the setup steps of G61
Superior Accuracy^
Dexcom G7 is our most accurate CGM system3 giving people living with diabetes the confidence to make informed diabetes decisions.
Dexcom CGM systems have been studied in over 250 registered clinical trials.#
- 8.2% overall adult MARD‡ (back of the arm)4
- 8.1% overall paediatric MARD‡ (back of the arm)5
- For Paediatrics, after the initial 24 hours the MARD was below 8% for the remaining days of wear5
- 95.3% of the sensor readings (upper arm) fall within ±1.1 mmol/L of the YSI blood glucose values <3.9 mmol/L and within ±20% of YSI blood glucose values ≥3.9 mmol/L4,5
Better Health Outcomes
Dexcom G7 offers predictive alerts with the Urgent Low Soon (ULS) feature enabling proactive intervention to prevent severe hypoglycaemia or rebound hyperglycaemic episodes6
REDUCTION OF HbA1c BY 1.0% FOR PATIENTS WITH T1D7
Dexcom CGM System users on a multiple daily injections (MDI) insulin regimen showed an average HbA1c reduction of 1% after 24 weeks of regular use, compared to baseline. Additionally, 52% of subjects in the study had a ≥1% HbA1c reduction.7
INCREASED TIME IN RANGE8
In a trial where Dexcom G6 powered the Tandem hybrid closed-loop system with Control-IQ, participants with type 1 diabetes increased their time in range (TIR) by 11% for Tandem AID users, allowing average blood glucose levels to stay in range longer.8
IMPROVEMENT IN QUALITY OF LIFE9
In this clinical trial, overall well-being improved during CGM use, treatment satisfaction was higher and hypoglycemia fear decreased in those using CGM.9
- The Urgent Low Soon (ULS) alert is associated with reduced hypoglycaemia, without a corresponding increase in rebound hyperglycaemia. In fact, severe hyperglycaemia decreased significantly**,§,10
- 97% of users enable the ULS alert6
- Hypoglycaemia remains a significant patient challenge. 95% of T1D patients and 64% of T2D patients experience hypoglycaemia^^,11
- Over half report a fear of hypoglycaemia ^^,11
*This product is indicated for persons with diabetes mellitus age 2 years and older where SMBG is indicated
^ As compared to Dexcom G6 System
# clinicaltrials.gov
** This predictive alert can be triggered with impending hypoglycemia (glucose of 3.1 mmol/L or below is predicted to occur within the the next 20 minutes)
§ Results obtained with a prior generation Dexcom CGM system with same Urgent Low Soon alert
^^ Based on Canadian population
1 Psavko S, et al. Usability and Teachability of Continuous Glucose Monitoring Devices in Older Adults and Diabetes Educators: Task Analysis and Ease-of-Use Survey. JMIR Hum Factors. 2022;9(4):e42057.
2 Dexcom G7 User Guide
3 Welsh JB, et al. Comparisons of Fifth-, Sixth-, and Seventh-Generation Continuous Glucose Monitoring Systems. J Diabetes Sci Technol. 2024;18(1):143-7.
4 Garg SK, et al. Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes. Diabetes Technol Ther. 2022;24(6):373-80.
5 Laffel LM,et al. Accuracy of a Seventh-Generation Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes. J Diabetes Sci Technol. 2023;17(4):962-7.
6 Puhr S, et al. Real-World Hypoglycemia Avoidance with a Continuous Glucose Monitoring System's Predictive Low Glucose Alert. Diabetes Technol Ther. 2019;21(4):155-8.
7 Beck RW, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA. 2017;317(4):371-8.
8 Brown SA, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. N Engl J Med. 2019;381(18):1707-17.
9 Lind M, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial. JAMA. 2017;317(4):379-87.
10 Acciaroli G, et al. Mitigation of Rebound Hyperglycemia With Real-Time Continuous Glucose Monitoring Data and Predictive Alerts. J Diabetes Sci Technol. 2022;16(3):677-82;
11 Aronson R, et al. The Canadian Hypoglycemia Assessment Tool Program: Insights Into Rates and Implications of Hypoglycemia From an Observational Study. Can J Diabetes. 2018;42(1):11-7;